[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100338225":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":24,"centralContacts":29,"locations":34,"responsibleParty":51,"collaborators":53,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":20,"eligibilityCriteria":62,"healthyVolunteers":59,"sex":63,"minAge":64,"maxAge":20,"enrollmentInfo":65,"targetDuration":20,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Dana-Farber Cancer Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MRiS","EXPERIMENTAL","* The specimens to be collected will include at least five pleural biopsy samples\n* MPT test and the CLDN15\u002FVIM test will be performed",[13,14],"Other: MPT Test","Other: CLDN15\u002FVIM Test",[16,21],{"type":6,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"MPT Test","molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms",[9],null,{"type":6,"name":22,"description":18,"armGroupLabels":23,"otherNames":20},"CLDN15\u002FVIM Test",[9],[25],{"name":26,"affiliation":27,"role":28},"Raphael Bueno, MD","Brigham and Women's Hospital","PRINCIPAL_INVESTIGATOR",[30],{"name":26,"role":31,"phone":32,"phoneExt":20,"email":33},"CONTACT","617-732-5690","rbueno@partners.org",[35],{"facility":27,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Boston","Massachusetts","02215","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-71.05977,42.35843,{"lat":46,"lon":45},[49,50],{"name":26,"role":31,"phone":32,"phoneExt":20,"email":33},{"name":26,"role":28,"phone":20,"phoneExt":20,"email":20},{"type":28,"investigatorFullName":26,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Principal Investigator",[54],{"name":55,"class":56},"National Cancer Institute (NCI)","NIH","100338225","prospectively-collected-pleural-biopsies-for-validation-of-malignant-pleural-mesothelioma-prognostic-biomarkers-100338225",false,"NCT03683680","Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers","Inclusion Criteria:\n\n* All adult patients with a diagnosis of malignant pleural mesothelioma undergoing\n\n  * diagnostic pleural biopsy\n  * pleuroscopy\n  * and\u002For VATS resections\n* Participants must be 18 years of age or older.\n\nExclusion Criteria:\n\n-Any patient who is found to be unsuitable for\n\n* surgery,\n* treatment\n* diagnosis,","ALL","18 Years",{"count":66,"type":67},240,"ESTIMATED","INTERVENTIONAL",[70],"NA","This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.",[73],"Mesothelioma",[73],"2026-04-29",{"date":77,"type":78},"2026-05-05","ACTUAL",{"date":80,"type":78},"2018-10-31",{"date":82,"type":67},"2030-10-01",{"name":5,"class":6},1]